The Other Names for Semaglutide — and Why the Brand Name Matters

The common misconception: that all semaglutide brands are interchangeable

Search for semaglutide's other name and you'll quickly find Ozempic listed alongside Wegovy as though they're the same thing sold in different boxes. They contain the same active molecule, yes, but UK medicines law licenses each brand for a specific purpose, and that distinction is not cosmetic. The MHRA licenses medicines; it licensed Ozempic for type 2 diabetes and Wegovy for weight management. They are not interchangeable in clinical practice, and a pharmacist cannot simply swap one for the other.

This matters practically. Someone who has seen Ozempic mentioned in the press and asks their GP for it in order to lose weight is asking for a medicine outside its licensed indication. A prescriber can act outside a licence in specific, documented circumstances, but that is not the same as the medicine being approved for that purpose, and it carries additional professional and clinical responsibility. The NHS overview of semaglutide explains the distinction between indications clearly, and it is worth reading before any consultation.

So if you want to understand what another name for semaglutide actually refers to, the most useful answer is not just a list, it is an understanding of why those names exist and what each one is actually for.

Wegovy, Ozempic and Rybelsus: what each brand is licensed for in the UK

Wegovy (injection): licensed for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. It is the injection form most people mean when they ask about semaglutide for weight loss. The maintenance pathway runs from 0.25 mg up to 2.4 mg weekly, titrated by the prescriber over roughly four months. NICE recommends it under specific criteria, including use within a specialist weight management service for a maximum of two years, as set out in NICE technology appraisal TA875.

Wegovy tablets: the newest form. The MHRA approved oral semaglutide for weight management on 11 June 2026, making the UK the first country in Europe to authorise it. The tablet escalates from 1.5 mg through 4 mg and 9 mg to a 25 mg maintenance dose. No refrigeration is needed, which some people find genuinely useful for travel. If you want context on how the tablet's results compare to the injection, our Wegovy guide covers the evidence in full.

Ozempic: semaglutide by injection, but licensed for type 2 diabetes, not weight loss. It is not available through nume for weight management, and we would never present it as an option for that purpose.

Rybelsus: oral semaglutide at 3 mg, 7 mg or 14 mg, the diabetes tablet. Those strengths are entirely separate from the Wegovy weight-loss tablet schedule and must not be confused with it. Anyone researching what Wegovy's other name is in the context of weight loss should be clear that Rybelsus is outside that lane.

Why you will sometimes see semaglutide referred to by its peptide or chemical name

In clinical literature you may encounter semaglutide described by its drug class rather than any brand: a GLP-1 receptor agonist, or more formally a glucagon-like peptide-1 receptor agonist. That is a description of how it works, not another brand name. Semaglutide binds to GLP-1 receptors, slowing gastric emptying and reducing appetite signals in the brain. The molecule itself has no other common name in UK clinical use beyond "semaglutide"; the brand names are purely commercial identifiers.

If you are curious about how the patent landscape might affect future naming and availability, our page on semaglutide's loss of exclusivity explains what that could mean for UK patients over the coming years.

For a fuller look at semaglutide as an ingredient across all its forms, our semaglutide overview pulls together the clinical background in one place.

Getting the right semaglutide product through a regulated route

Because these distinctions matter clinically, the route to the right product starts with a proper consultation, not a quick search for whichever brand looks cheapest online. At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber. There is no algorithm making the decision; a real clinician works through your answers. If treatment is appropriate, the medicine is dispensed from our GPhC-registered pharmacy (9012878) and arrives via DPD in plain, unbranded packaging, the pen itself, correctly labelled, with its patient information leaflet.

If you are thinking about weight management treatment and want to understand what is available, our treatment overview is the clearest starting point. For broader context on how the different options sit alongside each other, our weight-loss guide covers the full picture. And if questions about cost are on your mind, our Wegovy pricing page explains what private treatment typically involves.

One thing worth saying plainly: with a prescription medicine, the brand name on the box is far less important than whether the prescriber who approved it actually reviewed your health, and whether the pharmacy dispensing it is regulated and accountable. Those questions are worth asking of any provider. Check your eligibility and speak to our prescribers at joinnume.co.uk.